
Verastem scores FDA nod for first-of-its-kind oral combination to treat rare form of ovarian cancer
In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination treatment of avutometinib and defactinib for a rare form of ovarian cancer. With the commercial name of Avmapki Fakzynja Co-Pack, the …